The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective

Thumbnail
Fulltext:
201379.pdf
Size:
641.0Kb
Format:
PDF
Description:
Publisher’s version
Download
Publication year
2018
Author(s)
Asten, F. van
Michels, C.T.J.
Hoyng, C.B.
Wilt, G.J. van der
Klevering, B.J.
Rovers, M.M.
Grutters, J.P.C.
Source
PLoS One, 13, 5, (2018), article e0197670
ISSN
DOI
Publication type
Article / Letter to editor
Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/201379   https://hdl.handle.net/2066/201379
Display more details

Upload full text

Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.